<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01712997</url>
  </required_header>
  <id_info>
    <org_study_id>BIPH-20121022</org_study_id>
    <nct_id>NCT01712997</nct_id>
  </id_info>
  <brief_title>Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients</brief_title>
  <acronym>BIPH</acronym>
  <official_title>Phase Ⅲ Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Arterial Hypertension Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fourth Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies suggest that combinations of existing therapies may be effective for
      pulmonary arterial hypertension (PAH). However, all of these studies are sequential
      combination therapy, for example, by adding sildenafil to previously prescribed bosentan.
      This kind of therapy model is not enough for PAH patients, especially those with New York
      Heart Association (NYHA) class Ⅲ and Ⅳ. In this randomized, multicenter study, the
      investigators evaluate the safety and efficacy of combining inhaled iloprost, a prostacyclin
      analog, with the endothelin receptor antagonist bosentan in treatment naive patients with PAH
      by comparing with bosentan monotherapy. Efficacy endpoints include change from baseline in
      6-min-walk distance (6-MWD), modified (NYHA) functional class, hemodynamic parameters, and
      time to clinical worsening.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline in 6-min-walk distance (6-MWD)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>modified (NYHA) functional class</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>time to clinical worsening</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combine inhaled iloprost, 10μg, 4-6times/day with bosentan,125mg,po,bid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bosentan,125mg,po,bid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iloprost</intervention_name>
    <arm_group_label>Combination therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosentan</intervention_name>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_label>monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 10 to 80

          -  treatment naive symptomatic PAH

          -  6-MWD of 100-425 m

          -  resting mean pulmonary artery pressure greater than 25 mm Hg, pulmonary capillary
             wedge pressure less than 15 mm Hg, and pulmonary vascular resistance of 240 dyn.s.cm-5
             or greater.

        Exclusion Criteria:

          -  Patients with thromboembolic disease,

          -  untreated obstructive sleep apnea,

          -  portal hypertension,

          -  chronic liver disease or renal insufficiency,

          -  left-sided or unrepaired congenital heart disease,

          -  substantial obstructive (FEV1/FVC&lt;50% predicted) or restrictive (total lung
             capacity&lt;60% predicted) lung disease

          -  Patients receiving phosphodiesterase inhibitors or other prostanoids and endothelin
             receptor antagonists
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shengqing Li, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The department of pulmonary and critical care medicine, Xijing hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shengqing Li, MD, PhD</last_name>
    <phone>+86-29-84771132</phone>
    <email>shengqingli@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The department of pulmonary and critical care medicine, Tangdu hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yonghong Xie, MD</last_name>
      <phone>+86-29-84777725</phone>
      <email>xieyh65@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Yonghong Xie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The department of pulmonary and critical care medicine, Xijing hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinpeng Han, MD</last_name>
      <phone>+86-29-84775237</phone>
      <email>hxp0728@163.com</email>
    </contact>
    <investigator>
      <last_name>Xinpeng Han, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yongping Yu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2012</study_first_submitted>
  <study_first_submitted_qc>October 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2012</study_first_posted>
  <last_update_submitted>February 26, 2014</last_update_submitted>
  <last_update_submitted_qc>February 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fourth Military Medical University</investigator_affiliation>
    <investigator_full_name>Shengqing Li</investigator_full_name>
    <investigator_title>Associate Chief Physician, Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Treatment of</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
    <mesh_term>Iloprost</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 23, 2016</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>July 7, 2016</submitted>
    <returned>August 18, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

